Floatz logo

Trabectedin

BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype

Catholic University of the Sacred HeartSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype cohort.

Asset / SponsorPhaseRating
Olaparib
VA Office of Research and Development
Phase 3BB
Carboplatin
VA Office of Research and Development
Phase 2BB
Letrozole
UNICANCER
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
University Health Network, Toronto
Phase 2/3BB
Veliparib
AbbVie
Phase 2BB

View all 26 →

Same molecule, other indications

Trabectedin is also rated in:

ovarian carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
ovarian neoplasmDormant
B
Indicative ·
63 / 100
View asset →
metastatic neoplasmDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →